Peripheral Arterial Disease, also known as PAD, is a growing concern in regards to cardiovascular issues around the world. The number of incidences have significantly increased the rate of morbidity and decreased the overall quality of life for a number of at-risk people. Because of this, people warrant special consideration to ensure early detection.
From among these people, diabetic patients or ones at risk for it require consideration and proactive testing. This is essential as diabetes increases the chances for them developing PAD by 2- to 4-fold. If the disease is undiagnosed and ignored, life-threatening complications might arise. Ankle-Brachial Pressure Index is one of the most effective ways to keep a track of PAD.
For years, medical health professionals have used the Doppler Probe to measure ABPI. But thanks to technological advancement in the medical field, new and improved devices have surfaced.
MESI ABPI MD or the MESI Ankle-Brachial Pressure Index Measuring Device offers an innovative measuring alternative to the much older technologies. Compared to the handheld Doppler that has been in use for years, the MESI ABPI measuring device offers objective and more accurate readings due to the automated technology it is based on.
To give you an idea of how much of an improvement MESI ABPI MD brings in ABPI measurement, here is a comparison between the regular handheld Doppler probe and the device itself.
In order to eliminate reading errors, the American Heart Association suggests a resting time before measuring blood pressure. When it comes to using a handheld Doppler, the general resting time required is anywhere between 10 and 29 minutes. The MESI ABPI MD, on the other hand, requires close to 0 minutes of pre-measurement resting time. Besides saving time, this also eliminates blood pressure drift error.
Speed and efficiency are both incredibly important when it comes to diagnostics. If blocked arteries can be detected in PAD’s early stages, the patients have a much better healing potential and augmented the quality of life.
The measurement with the Doppler probe, including resting time and manual calculation can take about 30 minutes. Compared to that, MESI ABPI MD uses Plethysmographic technology, which provides a safe, simultaneous 3CUFF measurement and completes the screening within a minute. This makes the device one of the fastest ABPI screening devices.
One of the most contrasting differences between the Doppler and MESI ABPI MD is that the latter allows simultaneous measurements. With the Doppler, the medical professional has to measure one extremity at a time.
MESI ABPI MD has three cuffs that can be attached to the person’s extremities at the same time. The red cuff is made to go on the upper arm and the yellow and green cuffs on the left and right ankles respectively. The device does not provide simple pressure measurements: due to the PADsense algorithm, the inflation and deflation are controlled. This allows for simultaneous measurement, making the process much faster and efficient.
When it comes to the actual pressure readings, the Doppler requires the medical professional to manually calculate the index. Since the MESI ABPI measuring device is designed with smart software and Plethysmographic sensors that automate the calculation with more accuracy, the measurement is objective and eliminates human error.
As an additional perk, the MESI ABPI device generates an automatic report, equipped with Pulse Waveforms, that can be analyzed on a PC and then printed out, whereas a Doppler doesn’t.
Conducting a measurement with the handheld Doppler probe also requires the medical staff to be specifically trained. Whereas, all medical professionals are already familiar with cuffs and need only to place them on the right extremities to get a reading.
Collectively, the differences between the two devices prove the MESI ABPI measuring device to be a faster and more efficient screening device than the standard Doppler. The device is an overall improvement in terms of performing an Ankle-Brachial Pressure Index measurement on all patients in the risk group with the aim to detect the ones affected by the disease in the early stages, making the process more efficient.
Are you interested to purchase the MESI ABPI MD?